Ono Pharmaceutical Co., Ltd. (OPHLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ono Pharmaceutical Co., Ltd. (OPHLF) trades at $14.90 with AI Score 59/100 (Grade B). Ono Pharmaceutical Co. , Ltd. is a Japanese pharmaceutical company focused on the development, manufacturing, and marketing of innovative drugs. Market cap: $7.00B, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for OPHLF: OPHLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OPHLF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OPHLF: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Ono Pharmaceutical Co., Ltd. (OPHLF) Healthcare & Pipeline Overview
Ono Pharmaceutical Co., Ltd., established in 1717, develops and markets pharmaceutical products and diagnostic reagents globally. With a diverse portfolio spanning oncology, diabetes, and immunology, the company maintains a strong presence in the healthcare sector, supported by collaborations and a robust pipeline, and currently has a market capitalization of $7.00B.
What Is the Investment Thesis for OPHLF?
Ono Pharmaceutical presents a compelling investment case based on its established market presence, diverse product portfolio, and strategic collaborations. With a P/E ratio of 15.4 and a profit margin of 12.3%, the company demonstrates financial stability. Growth catalysts include the expansion of existing product lines like Opdivo and Forxiga, as well as the development of new therapies in its pipeline. The company's dividend yield of 3.39% offers an attractive return for investors. However, potential risks include regulatory hurdles, competition from other pharmaceutical companies, and the inherent uncertainties of drug development. The company's beta of 0.10 suggests low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
OPHLF Key Highlights
- Market capitalization of $7.00B indicates substantial company size and investor confidence.
- P/E ratio of 15.4 suggests a reasonable valuation compared to earnings.
- Profit margin of 12.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 69.8% reflects efficient cost management in the production and sales of pharmaceuticals.
- Dividend yield of 3.39% provides a steady income stream for investors.
Who Are OPHLF's Competitors?
OPHLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DSRLF DiaSorin S.p.A. | $84.10 | +13.27% | $4.16B | 52 |
| FLMNF Fielmann AG | $52.85 | +4.14% | $4.44B | 50 |
| GZPHF Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.20B | 43 |
| HKMPF Hikma Pharmaceuticals PLC | $19.07 | -5.20% | $4.01B | 45 |
| HKMPY Hikma Pharmaceuticals PLC | $41.03 | -0.49% | $4.32B | 45 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPHLF's Key Strengths?
- Innovative drug pipeline
- Strong market position in Japan
- Strategic collaborations with leading research institutions
- Diverse product portfolio
What Are OPHLF's Weaknesses?
- Reliance on a few key products
- Limited presence in some emerging markets
- Exposure to generic competition
- OTC listing may limit access to capital
What Could Drive OPHLF Stock Higher?
- Clinical trial results for novel therapies in the pipeline.
- Regulatory approvals for new indications of existing drugs.
- Expansion of strategic collaborations and partnerships.
- Increasing demand for pharmaceutical products in emerging markets.
- Development of digital health solutions to improve patient outcomes.
What Are the Key Risks for OPHLF?
- Regulatory changes and pricing pressures could impact revenue.
- Competition from other pharmaceutical companies could erode market share.
- Patent expirations could lead to generic competition.
- The inherent uncertainties of drug development could result in clinical trial failures.
- Economic downturns could reduce demand for pharmaceutical products.
What Are the Growth Opportunities for OPHLF?
- Expansion of Opdivo's Indications: Ono Pharmaceutical has the opportunity to expand the approved indications for Opdivo, its leading oncology drug. This includes pursuing approvals for new cancer types and combination therapies. The global oncology market is projected to reach $286.6 billion by 2031, providing a substantial market for Opdivo's continued growth. Timeline: Ongoing clinical trials and regulatory submissions.
- Development of Novel Therapies: Ono Pharmaceutical's pipeline includes several promising drug candidates targeting various diseases, including autoimmune disorders, neurological conditions, and other cancers. Successful development and commercialization of these therapies could significantly boost revenue. The market for autoimmune disease treatments is expected to reach $150 billion by 2028. Timeline: Clinical trials in progress with potential launches in the next 3-5 years.
- Strategic Collaborations and Acquisitions: Ono Pharmaceutical can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with biotech companies and research institutions can accelerate drug development and access new technologies. The company's existing collaborations with Adimab LLC and Turbine Ltd. demonstrate its commitment to this strategy. Timeline: Ongoing, with potential deals announced in the next 1-2 years.
- Geographic Expansion: Ono Pharmaceutical can expand its presence in emerging markets, such as China and India, where there is a growing demand for pharmaceutical products. This includes establishing local manufacturing facilities and distribution networks. The pharmaceutical market in emerging economies is expected to grow at a faster rate than developed markets. Timeline: Gradual expansion over the next 5-10 years.
- Digital Health Integration: Ono Pharmaceutical can leverage digital health technologies, such as telemedicine and mobile health apps, to improve patient outcomes and enhance its market reach. This includes developing digital therapeutics and remote monitoring solutions. The digital health market is projected to reach $660 billion by 2028. Timeline: Pilot programs and partnerships in the next 2-3 years, followed by broader implementation.
What Opportunities Does OPHLF Have?
- Expansion into new therapeutic areas
- Increased demand for pharmaceutical products in emerging markets
- Development of personalized medicine
- Leveraging digital health technologies
What Threats Does OPHLF Face?
- Regulatory changes and pricing pressures
- Competition from other pharmaceutical companies
- Patent expirations
- Economic downturns
What Are OPHLF's Competitive Advantages?
- Patented pharmaceutical products provide market exclusivity.
- Strong brand reputation in key therapeutic areas.
- Established relationships with healthcare providers and distributors.
- Extensive research and development capabilities.
What Does OPHLF Do?
Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Osaka, Japan, with a history stretching back to its founding in 1717. Initially a pharmaceutical wholesaler, the company transitioned to research and development, focusing on innovative drugs. Today, Ono Pharmaceutical develops, manufactures, and markets a wide range of pharmaceutical products and diagnostic reagents across several therapeutic areas, including oncology, diabetes, immunology, and neurology. Key products include Opdivo, an intravenous infusion for malignant tumors, and Glactiv, a tablet for type 2 diabetes. The company also offers treatments for chemotherapy-induced nausea, pheochromocytoma, and other conditions. Ono Pharmaceutical has expanded its global reach through strategic collaborations with companies like Adimab LLC, Turbine Ltd., Sibylla Biotech and academic institutions such as Harvard University. These collaborations enhance its research and development capabilities, allowing it to explore new therapeutic targets and technologies. The company's commitment to innovation and patient care has solidified its position as a key player in the pharmaceutical industry.
What Products and Services Does OPHLF Offer?
- Develops and markets pharmaceutical products and diagnostic reagents.
- Offers prescription drugs for oncology, diabetes, immunology, and neurology.
- Conducts research and development to discover new therapeutic targets.
- Manufactures pharmaceutical products in compliance with regulatory standards.
- Collaborates with other companies and research institutions to accelerate drug development.
- Distributes its products globally through a network of distributors and partners.
- Provides patient support programs to improve adherence and outcomes.
How Does OPHLF Make Money?
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Invests in research and development to create new products.
- Partners with other companies to expand its product portfolio and geographic reach.
What Industry Does OPHLF Operate In?
Ono Pharmaceutical operates within the global pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Ono Pharmaceutical competes with major pharmaceutical companies, including DSRLF (Daiichi Sankyo), FLMNF (Fuji Pharma), GZPHF (Guangzhou Baiyunshan Pharmaceutical), HKMPF (Lee's Pharmaceutical), and HKMPY (Hutchison Medipharma), all vying for market share in key therapeutic areas. The company's focus on innovative therapies and strategic collaborations positions it to capitalize on the growing demand for advanced medical treatments.
Who Are OPHLF's Key Customers?
- Hospitals and clinics
- Pharmacies
- Patients with various medical conditions
- Healthcare providers
FY2026 estForward Outlook
Wall Street analysts project Ono Pharmaceutical Co., Ltd. revenue of about $509.43B for fiscal 2026, with EPS near $152.48. The estimate reflects 6 contributing analysts.
OPHLF Valuation & Market Position
With a $7.00B market cap, Ono Pharmaceutical Co., Ltd. sits in the mid-cap segment of the market. Relative to its peer group, OPHLF's quantitative score of 59/100 is above the peer average of 47/100.
ROE 9%Key Financial Metrics
Return on equity for Ono Pharmaceutical Co., Ltd. stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.3%, showing how much profit it generates from its asset base. OPHLF trades at a trailing price-to-earnings ratio of 15.37, below the Healthcare sector average of ~23x. Its free cash flow yield is 11.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Ono Pharmaceutical Co., Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.60 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Ono Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Osaka, JP. The company is led by CEO Gyo Sagara. OPHLF has traded publicly since 2013.
OPHLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating management's belief in upcoming growth.
- Social sentiment has shifted positively, with increased discussions around Ono's innovative drug pipeline, attracting interest from investors.
- The pharmaceutical sector is seeing a resurgence, and Ono's focus on niche therapies positions it well in a competitive market.
- Recent partnerships and collaborations have enhanced Ono's research capabilities, suggesting potential for breakthrough developments.
Bear Case
- Despite positive sentiment, some analysts express concerns about regulatory hurdles that could delay product approvals.
- Community discussions reveal skepticism about the company's ability to scale its operations effectively amidst rising competition.
- There are lingering doubts regarding the sustainability of Ono's current revenue streams, with some investors worried about long-term growth.
- Market perception remains cautious as investors weigh the potential risks associated with ongoing clinical trials and their outcomes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
OPHLF Latest News
-
Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera
Yahoo! Finance: OPHLF News · Jun 17, 2026
-
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
businesswire.com · Jun 1, 2026
OPHLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPHLF.
Price Targets
Wall Street price target analysis for OPHLF.
OPHLF MoonshotScore
What does this score mean?
The MoonshotScore rates OPHLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
OPHLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ono Pharmaceutical may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Potential for price manipulation
- Increased regulatory scrutiny
- Higher risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Review the company's investor relations materials and communications.
- Check for any news articles or reports about the company's activities.
- Consult with a financial advisor before investing.
- Established history dating back to 1717
- Global presence and partnerships
- Diverse product portfolio
- Focus on research and development
- Market capitalization of $7.00B
Ono Pharmaceutical Co., Ltd. Healthcare Stock: Key Questions Answered
What does Ono Pharmaceutical Co., Ltd. do?
Ono Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. The company's primary focus is on prescription drugs, with a diverse portfolio spanning oncology, diabetes, immunology, and neurology. Ono Pharmaceutical generates revenue through the sale of these pharmaceutical products to hospitals, clinics, pharmacies, and healthcare providers worldwide, with a strong presence in the Japanese market and expanding global reach through strategic partnerships.
What are the main risks for OPHLF?
Ono Pharmaceutical faces several risks inherent to the pharmaceutical industry. These include regulatory risks related to drug approvals and pricing, competition from other pharmaceutical companies, and patent expirations that could lead to generic competition. Additionally, the company faces risks associated with the inherent uncertainties of drug development, including the potential for clinical trial failures and delays. As an OTC-listed stock, OPHLF also faces risks related to lower trading volume and liquidity, as well as increased regulatory scrutiny.
What are the key factors to evaluate for OPHLF?
Ono Pharmaceutical Co., Ltd. (OPHLF) holds an AI score of 59/100 (moderate). P/E: 15.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does OPHLF data refresh on this page?
OPHLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OPHLF's recent stock price performance?
Ono Pharmaceutical Co., Ltd. (OPHLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPHLF overvalued or undervalued right now?
Ono Pharmaceutical Co., Ltd. (OPHLF) trades at 15.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OPHLF?
Before investing in Ono Pharmaceutical Co., Ltd. (OPHLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OPHLF to a portfolio?
Key strength of Ono Pharmaceutical Co., Ltd. (OPHLF): Innovative drug pipeline. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or incomplete.
- AI analysis is pending and will provide further insights.